TP53 and B-cell chronic lymphocytic leukemia: Thornton et al. indicated only 7% TP53 abnormalities in the previously untreated group, while 50% of the heavily pretreated/refractory CLL group had abnormalities detected, indicating that p53 is associated with more aggressive disease and resistance to chemotherapy [447].